Tools for optimizing pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants

References

• 1. Eap CB, Gründer G, Baumann P et al. Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants. World J. Biol. Psychiatry doi:10.1080/15622975.2021.1878427, 1–68 (2021) (Epub ahead of print).
  MedlineGoogle Scholar
• 2. Hiemke C, Bergemann N, Clement HW et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 51(1–2), 9–62 (2018).
  Medline CASGoogle Scholar
• 3. Bousman CA, Bengesser SA, Aitchison KJ et al. Review and consensus on pharmacogenomic testing in psychiatry. Pharmacopsychiatry 54(1), 5–17 (2021).
  MedlineGoogle Scholar
• 4. De Crescenzo F, Ciliberto M, Menghini D et al. Is 18F-FDG-PET suitable to predict clinical response to the treatment of geriatric depression? A systematic review of PET studies. Aging Ment. Health 21(9), 889–894 (2017).
  MedlineGoogle Scholar
• 5. de Leon J. The future (or lack of future) of personalized prescription in psychiatry. Pharmacol. Res. 59(2), 81–89 (2009).
  MedlineGoogle Scholar
• 6. de Leon J. Evidence-based medicine versus personalized medicine: are they enemies? J. Clin. Psychopharmacol. 32(2), 153–164 (2012).
  MedlineGoogle Scholar
• 7. de Leon J. Pharmacogenomics: the promise of personalized medicine for CNS disorders. Neuropsychopharmacology 34(1), 159–172 (2009).
  Medline CASGoogle Scholar
• 8. de Leon J. Focusing on drug versus disease mechanisms and on clinical subgrouping to advance personalised medicine in psychiatry. Acta Neuropsychiatr. 26(6), 327–333 (2014).
  MedlineGoogle Scholar
• 9. Meyer UA. Pharmacogenetics – five decades of therapeutic lessons from genetic diversity. Nat. Rev. Genet. 5(9), 669–676 (2004).
  Medline CASGoogle Scholar
• 10. de Leon J. Phenoconversion and therapeutic drug monitoring. Br. J. Clin. Pharmacol. 80(4), 777–778 (2015).
  MedlineGoogle Scholar
• 11. de Leon J. Why do you keep telling me that drug–drug interactions are important in psychopharmacology when I do not see them in my clinical practice?: my failure to convince clinicians. J. Clin. Psychopharmacol. 39(1), 1–4 (2019).
  MedlineGoogle Scholar
• 12. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69(3), 89–95 (2001).
  MedlineGoogle Scholar
• 13. Wagner JA. Overview of biomarkers and surrogate endpoints in drug development. Dis. Markers 18, 41–46 (2002).
  Medline CASGoogle Scholar
• 14. Alawieh A, Zaraket FA, Li JL, Mondello S et al. Systems biology, bioinformatics, and biomarkers in neuropsychiatry. Front. Neurosci. 6, 187 (2012).
  MedlineGoogle Scholar
• 15. Veselinović T, Scharpenberg M, Heinze M et al. Dopamine D2 receptor occupancy estimated from plasma concentrations of four different antipsychotics and the subjective experience of physical and mental well-being in schizophrenia: results from the randomized NeSSy trial. J. Clin. Psychopharmacol. 39(6), 550–560 (2019).
  Medline CASGoogle Scholar
• 16. McCutcheon R, Beck K, Jauhar S et al. Defining the locus of opaminergic dysfunction in schizophrenia: a meta-analysis and test of the mesolimbic hypothesis. Schizophr. Bull. 44(6), 1301–1311 (2018).
  MedlineGoogle Scholar
• 17. Spina E, de Leon J. Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. Expert Opin. Drug Metab. Toxicol. 10(5), 721–746 (2014).
  Medline CASGoogle Scholar
• 18. de Leon J. A critical commentary on the 2017 AGNP consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology. Pharmacopsychiatry 51(1-02), 63–68 (2018).
  MedlineGoogle Scholar
• 19. Schoretsanitis G, Paulzen M, Unterecker S et al. TDM in psychiatry and neurology: a comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. World J. Biol. Psychiatry 19(3), 162–174 (2018).
  MedlineGoogle Scholar
• 20. Schoretsanitis G, Kane JM, Correll CU et al. Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology and the therapeutic drug monitoring task force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. J. Clin. Psychiatry 81(3), 19cs13169 (2020).
  MedlineGoogle Scholar